Pfizer's antiviral pill for Covid-19 is nearly 90 per cent effective in reducing the risk of serious disease, trial results suggest.
Today, the US pharmaceutical giant released preliminary results of its study of 775 adults, which show the oral treatment cut the risk of hospitalisation or death by 89 per cent in vulnerable adults.
Pfizer said it will now ask regulators to authorise its pill, named Paxlovid, as soon as possible after independent experts recommended halting trials based on the strength of its results. READ: More than £5bn of Covid support cash was paid out because of fraud or error It comes after the Medicines and Healthcare products Regulatory Agency (MHRA) announced it had approved the first at-home antiviral for